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Abstract: Metastasis is the leading cause of cancer-related deaths and despite measurable progress
in the field, underlying mechanisms are still not fully understood. Circulating tumor cells (CTCs)
disseminate within the bloodstream, where most of them die due to the attack of the immune system.
On the other hand, recent evidence shows active interactions between CTCs and platelets, myeloid cells,
macrophages, neutrophils, and other hematopoietic cells that secrete immunosuppressive cytokines,
which aid CTCs to evade the immune system and enable metastasis. Platelets, for instance, regulate
inflammation, recruit neutrophils, and cause fibrin clots, which may protect CTCs from the attack
of Natural Killer cells or macrophages and facilitate extravasation. Recently, a correlation between the
commensal microbiota and the inflammatory/immune tone of the organism has been stablished. Thus,
the microbiota may affect the development of cancer-promoting conditions. Furthermore, CTCs may
suffer phenotypic changes, as those caused by the epithelial–mesenchymal transition, that also contribute
to the immune escape and resistance to immunotherapy. In this review, we discuss the findings regarding
the collaborative biological events among CTCs, immune cells, and microbiome associated to immune
escape and metastatic progression.
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1. Introduction
The presence of circulating tumor cells (CTCs) in the peripheral blood has been largely associated
with reduced disease-free and overall survival [1–3]. Even though metastasis is a highly inefficient
process (tumor cell survival is less than 0.01%) [4], it is responsible for the majority of cancer-associated
deaths [5]. In fact, it is accepted that CTCs are the initiator factor of metastatic relapse and their presence
identifies patients with a higher risk of developing metastasis [6,7]. However, the complex biological
processes enabling CTCs to survive and disseminate is not yet well understood and little is known
about the cellular and genetic events involved both in the metastatic initiation and in its progression.
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The success of the metastatic process is conditioned by the established relationship between
tumor cells and the surrounding microenvironment. During the metastatic process, tumor cells
interact with the immune system, which modulates this process [8]. The immune system has a dual
role, both repressing but also promoting cancer progression. In fact, formation of CTC clusters or
microemboli, not only composed of CTCs but also leukocytes, cancer-associated fibroblasts, endothelial
cells, and platelets, was shown to facilitate the metastatic process and thus be related to poorer outcome
in patients with breast [9] and gastric cancer [10], among others.
In this review, we will focus our interest in the “intimate friendship" between CTCs and the
immune system. This private alliance benefits tumor progression through CTCs survival in this hostile
microenvironment, the blood.
However, we cannot forget that the microenvironment is not only composed by immune system
cells, stromal cells, and components of the extracellular matrix (ECM). CTCs and microbes co-evolve
inside the ecosystem within our bodies [11,12] as will be further described in Section 3. This interaction
influences the activity of the immune system on cell survival and expansion of CTCs [13].
In this review, we evaluate the current literature on interactions among CTCs, immune system
cells, and microbiome in the tumor progression. We discuss how immune cells–CTC interactions
contribute to the survival of these CTCs and how the microbiome can promote this positive association,
finally supporting the metastatic process.
2. Promotion of Circulating Tumor Cells through the Immune System
The immune system is educated to eliminate the foreign and to respect the innate [14]. However,
in the case of cancer, tumor cells are able to use the immune system to facilitate their own survival and
migration. This phenomenon is known as concomitant immunity (CI) [15,16].
The plasticity of the immune system is well known and thus, according with the tumor type,
the functional contribution of each immune cell can also be different [17,18]. However, some immune events
are intimately associated with promotion of cancer, independently on the tumor type. Inflammation is one
of these events and it is recognized as one of the “hallmarks” of cancer [19]. This process involves different
types of immune cells, among which platelets, macrophages, and neutrophils can be highlighted [20,21].
Platelets are anucleated blood cells with a diameter of 2–4 µm originated during megakaryocytes
maturation in the bone marrow and circulate in large numbers (1.5–4.0 × 109/L) in the bloodstream [22,23].
Platelets are the main cells involved in thrombosis and hemostasis, thus, related with the physiological
and pathophysiological processes occurring during inflammation [24]. Interestingly, several studies
have reported their role in cancer progression, especially during cancer metastasis [25] as they actively
promote the metastatic process. Metastasis-promoting mechanisms affected by platelets are related to both
migration of tumor cells and cancer cell survival in circulation [26].
Regarding the migration process, platelets store large amounts of transforming growth factor β
(TGFβ), which is associated with an increase of the invasion potential of tumor cells. Thus, tumor
cells-conjugated platelets release mediators to modify blood vessels permeability, including dense
granule-release, histamine, eicosanoid metabolites, or serotonin [23]. These mediators induce endothelial
cell retraction, exposing the basement membrane, and thus facilitate cancer cell extravasation [27].
In addition, platelets activation by cancer cells lead to the generation of platelet-derived microparticles
(PDMPs), which can also release mediators like TxA2 and 12-HETE. These metabolites may enhance cell
migration and invasion, eventually increasing the metastatic potential of cancer cells [28].
However, self-migration ability of CTCs is not enough to complete a successful metastatic process,
survival of these cells, once in the blood, depends on the formation of circulating microemboli [9] as
well as the acquisition of resistant phenotypes to the surrounding microenvironment. The acquisition
of these phenotypes involves a biological process known as epithelial to mesenchymal transition
(EMT) [29]. The EMT process explains how tumor cells change their phenotype, allowing them
to detach, invade, and metastasize through the blood or lymphatic systems. Among others, the EMT
involves loss of E-cadherin, disrupting cell-to-cell adhesions and altering gene expression by increasing
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β-catenin nuclear localization [30]. In contrast, N-cadherin, which is highly expressed in mesenchymal
cells, fibroblasts, neural tissue, and cancer cells, is elevated during EMT. This cadherin switch,
from E-cadherin to N-cadherin, is closely associated with the increased invasiveness, motility and
metastasis potential of tumor cells. Moreover, activated platelets induce EMT through secretion
of growth factors and cytokines (e.g., TNFα and TGFβ) [31]. Interestingly, these cytokines are also
associated with the inflammatory process as previously explained [32].
Furthermore, CTCs-conjugated platelets also coordinate the engagement of other immune
cells during the dissemination process [33]. In fact, CTCs-conjugated platelets recruit neutrophils,
macrophages, and other immune cells through release of chemokines, such as CXCL5 or CXCL7. Among
white blood cells (WBC), neutrophils are recognized as the mediators of metastasis initiation [34,35].
Neutrophils promote tumor development by initiating an angiogenic switch and facilitating colonization
of CTCs. In fact, some groups support the idea that WBC shape a protective cover around CTCs,
avoiding their recognition and destruction by other immune cells [36]. It has long been known that
circulating platelet–neutrophil complexes are present in a wide range of inflammatory conditions
including cancer. In this interaction, neutrophils are responsible to activate platelets and it was shown
that the neutrophils–platelets interaction initiates inflammatory responses [37]. Platelets interact with
neutrophils by multiple intermediates including platelet P-selectin binding to neutrophil P-selectin
glycoprotein ligand-1 (PSGL-1) [38]. In addition, it has been suggested that the neutrophils-platelets
complexes interacting to CTCs bring the latter to the endothelium, which is an essential step
in hematogenous dissemination metastasis [34]. Thus, platelets prime tumor cells to promote
neutrophil extracellular traps (NETs) formation, which are also involved in endothelial activation [39].
However, the interaction between the platelets–tumor cells complex and immune cells is not
only restricted to neutrophils. The release of CXCL12, which is highly present in platelets, allows
recruitment of CXCR4-positive cells such as macrophages to prepare the metastatic niche for CTCs [40].
Neutrophils are the first leukocytes to be recruited in response to chemotactic signaling and are
responsible for stimulating the repair process and initiating inflammation. This influx is followed by
monocytes, which, upon entry into the tissue, differentiate into macrophages. These macrophages
promote invasion and metastasis from the primary tumor site through their ability to engage cancer
cells in an autocrine loop that promotes cancer cell [41]. This autocrine signaling triggers cancer cells
to produce CSF-1, which promote epidermal growth factor (EGF) production by macrophages. Finally,
cancer cells and macrophages co-migrate towards tumor blood vessels, where macrophage-derived
VEGF-A promotes cancer cell intravasation [42]. In addition, tumor migration is upregulated by
macrophage-derived cathepsins, SPARC, or CCL18, that enhance tumor cell adhesion to extracellular
matrix proteins [41]. Finally, CTCs produce CCL2 that recruits inflammatory monocytes, which in turn
increase vascular permeability and allow migration of these tumor cells [16].
Nevertheless, migration and survival of CTCs belong together, so the promotion of CTC migration
alone is not enough to allow metastasis. Anoikis is a programmed cell death induced by cell
detachment [43] and essential for CTC survival. Another effect of the collaboration between immune
cells and CTCs includes the protection of CTCs from anoikis [44]. Platelets are involved in this protective
mechanism as it was observed that they induce RhoA-(myosin phosphatase targeting subunit 1) and
MYPT1-protein phosphatase (PP1)-mediated Yes-associated protein 1 (YAP1) dephosphorylation and
nuclear translocation, resulting in apoptosis resistance [45]. Apoptosis signal-regulating kinase 1
(Ask1) is a stress-responsive Ser/Thr mitogen-activated protein kinase kinase kinase (MAP3K) in the
Jun N-terminal kinases (JNK) and p38 pathways. Once Ask1 levels are reduced in platelets, active
phosphorylation of protein kinase B (Akt), JNK and p38 is downregulated, and thus tumor metastasis
is attenuated [46].
In conclusion, the fate of CTCs is not to survive alone but with help of their mates within the
immune system and thus, survival of CTCs depends on their ability to interact with immune cells.
However, this favorable interaction between CTC and immune cells depends also on the status of our
gut microbiota that is intimately linked with the nature of the immune system.
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3. Survival of Circulating Tumor Cells Through the Interaction of Microbiota with the Immune
System
The evolution of any disease, including cancer, depends highly on the physiological status
of the host. The gut microbiota has emerged as an important factor of health and disease [47].
Likewise, our microbiota conditions the status of our immune system [48]. In fact, gut microorganisms
are involved in the immune system development and in the response of the host against different
pathologies, like cancer. Taken together, tumor cells-microbiome-immune system interactions may
improve the likelihood of cell survival and induce tumor cell migration (Figure 1) [49].
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Figure 1. Interactions between circulating tumor cells (CTCs), immune system cells, and microbiome.
Metabolites and cytokines produced by bacteria such as Bacterioides fragilis, Enterococcus faecium, Escherichia
coli, and Fusobacterium nucleatum facilitate proliferation and migration of circulating tumor cells (CTCs),
promote stemness and epithelial to mesenchymal transition (EMT), and help CTCs to enter quiescence.
Furthermore, platelets interact with proliferating tumor cells directly, by formation of CTCs-platelet
complexes allowing CTCs to escape the immune system but also indirectly, through three different
ways: secretion of growth factors such as TFGβ, TNFα either alone or enclosed in platelets-derived
microparticles (PDMPs) that increase invasivity of CTCs; secretion of chemokines such as CXCL12,
increasing macrophages recruitment, what ultimately impact on invasivity and vessel permeability
through epidermal growth factor (EGF) and VEFG-A, respectively; and formation of platelet-neutrophil
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complexes (through P-selectin and PSGL1) that eventually generate neutrophil extracellular traps (NET)
promoting angiogenesis and facilitating CTC intravasation to blood vessels. Finally, macrophages and
NET also facilitate CTC extravasation from blood vessels to the extracellular matrix to produce metastasis.
As it has been mentioned before, the inflammatory process is an essential step in the development
and progression of cancer. Microbes have a critical role in the initiation and maintenance of chronic
inflammatory conditions [50,51]. However, how do microbes influence on the inflammation process
and on the migration and survival of CTCs?
The gut microbiota contributes to cancer progression through different mechanisms. Recently,
it was demonstrated that both, DNA-damaging superoxide radicals or genotoxins produced by the
gut bacteria could initiate colon cancer. In addition, bacteria may induce cell proliferation through
interactions with T-helper cells or Toll-like receptors, respectively [52]. In colon cancer patients,
an increase of the Escherichia coli population was observed to induce colitis and colibactin synthesis
and thereby, to promote inflammation.
Furthermore, it has been demonstrated that microbes as Bacillus sp., Enterococcus faecium, and E. coli
produce peptides which alter host epithelial growth factor, activating intracellular pathways associated
to migration. In a pioneer work, Wynendaele, E et al. [53] discovered that certain quorum sensing
peptides produced by bacteria (molecules that microbes use to coordinate their gene expression and
behavior) interact with cancer cells. This study demonstrated that Phr0662 (Bacillus sp.), EntF-metabolite
(E. faecium), and EDF-derived (E. coli) peptides can initiate HCT-8/E11 colon cancer cell invasion.
According to results of this group, the Phr0662 peptide targets epidermal growth factor receptors
(EGFR and ErbB2). Upregulation of EGFR induces activation of the Ras/raf/MEK/MAPK, PI3K/Akt,
and STAT intracellular signaling cascades [54] altering gene transcription and allowing migration
of tumor cells. However, despite this work being extremely interesting, it is only a preliminary and
exploratory in vitro assay and more exhaustive analyses including cancer patients should be carried
out to validate these results.
Microbes can also alter cancer cell epigenetics through production of metabolites affecting gene
expression [55]. This is the case of Bifidobacterium spp., which produces folate, one of the most powerful
methyl donors involved in gene silencing. Thus, the gut microbiome is also involved in chromatin
remodeling via acetylation and deacetylation of histones through butyrate production. Butyrate is
a common metabolite of the microbiome, inducing cell differentiation via histone acetylation of the
intestinal T reg cells [56].
Moreover, the microbiome plays an important role in the epithelial mesenchymal transition (EMT),
an essential step for CTC migration and survival. In fact, microbes produce toxins that contribute
to EMT [57]. Some of those microbes, as Bacteroides fragilis, Fusobacterium nucleatum, and E. faecalis,
clear E-cadherin from epithelial cells, a transmembrane adhesion protein, leading to colonic epithelial
proliferation [58]. Most of the studies on the interaction of the microbiome with cancer cells have been
developed on colon cancer, murine models, or in vitro assays. Likewise, in a recent study including
a murine model, colonic epithelial cells were transformed to express Ly6A/E, a stem cell marker
implicating mesenchymal features, and Doublecortin-like kinase 1 (DCKL1), a marker of cancer, by the
presence of E. faecalis [59]. DCLK1 is a member of the protein kinase super family and the doublecortin
family, which is overexpressed in many cancers, including colon, pancreas, liver, esophageal, and kidney
cancers. It is now suggested to be a master regulator of pluripotency factors, including Nanog, Oct4,
Sox2, Klf4, and Myc, that are critical for stemness of cancer cells (CSC, cancer stem cells) and EMT
transcriptional factors, including Snail, Slug, Twist, and Zeb 1 [60]. Interestingly, all these markers
are involved in regulation of both EMT and CSCs and are controlled by DCLK1 expression in cancer
models [61]. Furthermore, Westphalen, CB et al. [62], reported that DCLK1 induces quiescence of tumor
cells. Quiescence is a common property of CSCs that is associated with the EMT process as a critical
step for the migration and progression of tumor cells [63]. In consequence, EMT allows not only CTCs
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migration and tumor relapse, but also, induces the ability of CTCs to escape the immune system cancer
treatments (Figure 1) [64].
Another biological mechanism used by the microbiome to enhance cancer progression includes the
modulation of the immune system. Among all the microbes involved in this process, the enterotoxin
Bacteriodes fragilis (ETBF) stands up due to the activation of STATA3 and T helper cells, both with an
important role in the inflammatory process [65]. In fact, Chung, L et al. [65], demonstrated that Bacteroides
fragilis toxin (BFT) can activate a pro-carcinogenic inflammatory cascade, related to IL-17R, NF-κB, and
Stat3 signaling, in colonic epithelial cells (CECs). Likewise, the activation of NF-κB in these cells, induces
other chemokines as CXCL1 that mediates recruitment of CXCR2-expressing polymorphonuclear
immature myeloid cells, promoting ETBF-mediated distal colon tumorigenesis. Another bacterium
associated with poor oncological outcomes is Fuscobacterium nucleatum. It has been suggested that
F. nucleatum promotes tumorigenesis through both pro-inflammatory and immunosuppressive effects.
Furthermore, F. nucleatum is associated with activation of cytokines IL-6, IL-12, IL-17, and TNF-α,
which cooperatively upregulate NFκB, a critical regulator of cellular proliferation [66]. Some studies
associated the presence of high levels of F. nucleatum with the EMT process [67]. In this context,
Mima, K et al. [68], identified that F. nucleatum adheres to and invades epithelial cells mainly through
the virulence factors, including Fusobacterium adhesin A, Fusobacterium autotransporter protein 2,
and fusobacterial outer membrane protein. To the contrary, other studies raise their skepticism about
the role of F. nucleatum on EMT, as it still remains unclear whether F. nucleatum triggers the colonic EMT
process. Ma, CT, et al., showed that F. nucleatum infection did not affect expression levels of E-cadherin
and β-catenin [69]. However, it was associated with proliferation and invasion of colon cancer cells as
it significantly increased phosphorylation of p65 (a subunit of nuclear factor-κB), as well as expression
of interleukin (IL)-6, IL-1β and matrix metalloproteinase (MMP)-13. Regardless of the fact that there
are not any explicit studies evaluating the direct action of the microbiota on CTCs, we here reviewed
some of the biological processes in which microbes alter tumorigenic pathways. As they are involved
in inflammation or inducing EMT, both biological processes intimately associated with the ability
of CTCs to migrate and to survive, we suggest the potential interaction between them.
4. Conclusions and Perspectives
In conclusion, the complex interactions between the microbiome, the immune system and CTCs
may allow us to grasp the insights of the dissemination process occurring in cancer and the immune
system´s mechanisms involved in this process. Therefore, the interactions among microbiome, immune
system, and CTCs could aid the rational design of interventions that strengthen the antimetastatic
potential of combined treatments to prevent appearance of metastasis. Moreover, emerging evidences
may provide new mechanisms to control the dissemination process through the development of new
therapeutic strategies with the microbiota as target. However, this topic is still an incipient area
of research and further investigation is needed to clarify the association of the microbiome with the
immune system and the dissemination process.
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